Abstract: A piperidinyl-containing heterocyclic compound represented by formula (I). The compound can be used for treating a condition or disease related to complement alternative pathway activation by inhibiting/regulating complement factor B.

Abstract: The present disclosure provides an information processing method, device, electronic apparatus, and storage medium, including: displaying at least one workflow item on a current page in response to a workflow creation operation, and determining a selected item based on a first selection operation for the at least one workflow item, wherein the at least one workflow item includes a corresponding processing personnel; generating condition options corresponding to each selected item on the current page in response to a confirmation of the selected item, and determining an item condition for each selected item based on a second selection operation for the condition options; and generating and displaying a workflow preview interface on the current page based on the selected item and the item condition.

Abstract: The compound represented by formula (I), and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof have ROCK inhibitory activity. The compound represented by formula (1) has good safety, good metabolic stability, and a low risk of potential hepatotoxicity. Further, the compound represented by formula (I) has a simple preparation method and is easy to purify, and therefore has good application prospects.

Abstract: Disclosed are a heterocyclic compound, and an intermediate thereof, a preparation method therefor and the use thereof. Namely, provided are a heterocyclic compound as shown in formula I-a, and a tautomer and a pharmaceutically acceptable salt thereof, wherein the compound has a good water solubility and pharmacokinetic properties.

Abstract: The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.

Abstract: Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

Abstract: Disclosed are a pyrimidine carboxamide compound and an application thereof. Further provided are a pyrimidine carboxamide compound represented by formula (I), or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, a mixture form thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a Vanin enzyme inhibitor, and can be used to prepare a drug for treating various diseases, including Crohn's disease, ulcerative colitis, and so on.

Abstract: A pharmaceutically acceptable salt type and crystal form of a compound of formula (I), and a preparation method of the compound and an application thereof are provided.

Abstract: Disclosed is a heterocyclic compound as represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof. The compound has better inhibitory activity on TRPC5, has good metabolic stability in liver micro-particles, and has good clinical pharmacokinetic properties.

Abstract: A compound represented by formula I are provided. The stereoisomer, racemate, tautomer, isotopic label, prodrug or a pharmaceutically acceptable salt of the compound, and a pharmaceutical composition containing the compound, a preparation method, and medical use of the compound are further provided. The structure is as shown in formula I.

Abstract: A compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof are provided. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.

Abstract: A compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof are provided. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.

Abstract: Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

Abstract: The present disclosure provides a data processing method and apparatus, an electronic device, a storage medium, and a program product. The data processing method includes: displaying a first window at a first position of a first document in response to receiving a triggering operation on a first control in the first document, wherein the first window includes an approval flow list; and displaying approval flow information of a first approval flow at the first position of the first document in response to receiving a selection operation on the first approval flow in the approval flow list.

Abstract: Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 ?M or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.

Abstract: Certain triazole compounds have good LPAR1 antagonistic activity and selectivity, low toxicity, and good metabolic stability, and can be used for preventing or treating the LPAR1-related disease or disorder. The IC50 value of some triazole compounds can be below 300 nM, even 50 nM. The range of CC50 of the triazole compounds can be greater than 200 ?M. They also show good metabolic stability in human, fancy rats, and house mice.

Abstract: The present invention relates to a salt form and a crystal form of a Vanin enzyme inhibitor represented by formula I, a method for preparing same, and use thereof. The salt form is a salt formed by the compound represented by formula I with an acid, and the crystal form is selected from a crystal form A, a crystal form B, a crystal form C, and a crystal form D of an L-tartrate of the compound represented by formula I. The salt of the compound represented by formula I of the present invention features high stability and good water solubility, which is conducive to the enhancement of oral absorbability, thus improving the bioavailability. The crystal form of the present invention features high stability, good solubility, and low hygroscopicity, and has promising prospects for being developed into medicaments.

Abstract: A compound having inhibitory activity for the lectin pathway of complement, a preparation method therefor, and an application thereof are provided. The compound has the general formula (I?). The compound and the pharmaceutically acceptable salt thereof can serve as a MASP-2 inhibitor, and can be in a drug for treating diseases such as IgA nephropathy, TA-TMA, aHUS, and lupus nephritis.

Abstract: Provided herein is the use of indazole compounds represented by formula (I), or a stereoisomer, a racemate, a tautomer, an isotopically labeled compound, a prodrug, or a pharmaceutically acceptable salt thereof, in the manufacture of medicament for treating and/or preventing psoriasis.

Abstract: Disclosed is a use of a heterocyclic compound. Specifically disclosed is a use of a heterocyclic compound in the preparation of a drug for treating and/or preventing respiratory diseases; the heterocyclic compound is a substance X, a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof; the substance X is a compound as shown in formula I or a compound as shown in formula II; the heterocyclic compound of the present invention has a good cough relieving effect.